One detail that trips up a lot of people trying to understand when a "generic" version of a peptide drug might become available is that not all peptide drugs are regulated, or listed, the same way. The FDA actually maintains two separate reference publications, and which one a drug falls under has real consequences for how copies of it eventually reach the market.
What the Orange Book Is
The Orange Book, formally "Approved Drug Products with Therapeutic Equivalence Evaluations," is the FDA's listing of drugs approved under a New Drug Application (NDA), the traditional pathway most small-molecule chemical drugs go through. It's the reference used to determine whether a proposed generic version is therapeutically equivalent to a brand-name product, and it also lists patents and periods of marketing exclusivity that can delay generic competition.
What the Purple Book Is
The Purple Book, "Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations," covers products approved as biologics under a Biologics License Application (BLA). Instead of generics, biologics get biosimilars, products that must show they are highly similar to the original with no clinically meaningful differences, but which are not required to be structurally identical the way a small-molecule generic is to its brand-name counterpart.
Why Some Peptides Are in One Book and Not the Other
Here's where it gets genuinely confusing for peptide drugs specifically: the FDA's dividing line between "small molecule" (NDA/Orange Book) and "biologic" (BLA/Purple Book) is partly based on molecular size and manufacturing complexity, and peptides sit awkwardly close to that line. Many synthetic peptides, including semaglutide and tirzepatide, are regulated as NDA drugs and appear in the Orange Book, meaning they are eligible for conventional small-molecule generic competition once patents and exclusivity expire. Other peptide and protein-based drugs, particularly larger or more structurally complex ones, are regulated as biologics under a BLA and appear in the Purple Book instead, meaning any future competition would come as a biosimilar, a more involved and expensive process for a would-be competitor than filing an abbreviated generic application.
Why This Matters for Drug Prices
This classification has direct, practical consequences for consumers: generic competition under the Orange Book pathway has historically driven prices down faster and further than biosimilar competition has for biologics, partly because the approval bar and manufacturing investment required for a biosimilar are higher. This site's separate coverage of semaglutide and tirzepatide patent timelines explains why true generic versions of those specific drugs are still years away even though they're Orange Book-listed NDA drugs, since patents and exclusivity periods, tracked in the Orange Book itself, are the actual gating factor, not the classification pathway alone.
How to Check for Yourself
Both books are public and searchable directly on the FDA's website, and looking up a specific drug there is a more reliable way to understand its exclusivity and generic-competition status than relying on secondhand summaries, including this one, since the underlying data updates as patents expire or new exclusivity periods are granted.
The Bottom Line
Whether a peptide drug is a "small molecule" or a "biologic" in the FDA's eyes isn't just a technical label, it determines whether its future competition comes from cheaper conventional generics or from the more complex, typically costlier biosimilar pathway, which is one of several reasons two seemingly similar peptide drugs can have very different timelines to lower-cost alternatives.